Colorectal Carcinoma with Genetic Abnormalities

subtype

Identifier: CI-CAN-00007526
Entity page: /cancer/colorectal-carcinoma-with-genetic-abnormalities ↗
Edges: 51

Neighbours: 16 drugs10 trials
Drawn: 26 of 26 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Colorectal Carcinoma with Genetic Abnormalities approved for …APPROVED_FORderived3 of 3
← approved for	Nivolumabmonoclonal antibody FDA (US) · approved · 2014-12-22 · Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-…	—	approved	dMMR Colorectal Carcinoma	1	Regulatory	openfda	graph →
← approved for	Pembrolizumab

Colorectal Carcinoma with Genetic Abnormalities investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 17show all (up to 200)
→ investigated in trials for	Capecitabinesmall molecule 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Colorectal Carcinoma with Genetic Abnormalities	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Colorectal Carcinoma with Genetic Abnormalities	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Colorectal Carcinoma with Genetic Abnormalities	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Panitumumabmonoclonal antibody 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Colorectal Carcinoma with Genetic Abnormalities	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Tislelizumabmonoclonal antibody 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Colorectal Carcinoma with Genetic Abnormalities	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Trastuzumabmonoclonal antibody 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Colorectal Carcinoma with Genetic Abnormalities	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Tucatinibsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Colorectal Carcinoma with Genetic Abnormalities	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Afliberceptother 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Colorectal Carcinoma with Genetic Abnormalities	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Colorectal Carcinoma with Genetic Abnormalities	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Dostarlimabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Colorectal Carcinoma with Genetic Abnormalities	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipilimumab/Nivolumab Regimen 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Colorectal Carcinoma with Genetic Abnormalities	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Colorectal Carcinoma with Genetic Abnormalities	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Levoleucovorinsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Colorectal Carcinoma with Genetic Abnormalities	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Niraparibsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Colorectal Carcinoma with Genetic Abnormalities	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Colorectal Carcinoma with Genetic Abnormalities	1	Observed	clinicaltrials	graph →

Colorectal Carcinoma with Genetic Abnormalities investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 17show all (up to 200)

→ investigated in trials for

Capecitabinesmall molecule

3 trials (0 active) · roll-up of the cancer and its descendants

—

Colorectal Carcinoma with Genetic Abnormalities

Observed

Colorectal Carcinoma with Genetic Abnormalities studied in …STUDIED_INderived10 of 31show all (up to 200)
→ studied in	NCT06253871Phase 1 · recruiting A Phase 1/1b Study of IAM1363 in HER2 Cancers · condition mapped ALIAS · 31 trials mapped (14 active)	—	—	HER2-Positive Colorectal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07689812NA · not yet recruiting A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. · condition mapped ALIAS · 31 trials mapped (14 active)	—	—	dMMR Colorectal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05714553Phase 1/Phase 2 · terminated NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours · condition mapped ALIAS · 31 trials mapped (14 active)	—	—	MSI-H Colorectal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05520099active not recruiting Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02) · condition mapped ALIAS · 31 trials mapped (14 active)	—	—	MSI-H Colorectal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07327489recruiting Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05) · condition mapped ALIAS · 31 trials mapped (14 active)	—	—	dMMR Colorectal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05514717Phase 1 · terminated A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 · condition mapped ALIAS · 31 trials mapped (14 active)	—	—	HER2-Positive Colorectal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05239546Phase 2 · recruiting Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers · condition mapped ALIAS · 31 trials mapped (14 active)	—	—	dMMR Colorectal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06152523Phase 2 · withdrawn Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer · condition mapped ALIAS · 31 trials mapped (14 active)	—	—	dMMR Colorectal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07409844Phase 2 · not yet recruiting Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer · condition mapped ALIAS · 31 trials mapped (14 active)	—	—	dMMR Colorectal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05062889Phase 2 · suspended Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients · condition mapped ALIAS · 31 trials mapped (14 active)	—	—	RAS Wild-Type Colon Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains